SCHEMBL6578645

SCHEMBL6578645

Cc1ccc(-n2c(=O)ccc3ccc(OS(=O)(=O)C(F)(F)F)cc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.40
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CYP19A1 P11511 1/20 0.35
PLA2G10 O15496 3/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
TP53 P04637 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NOTUM Q6P988 1/20 0.33
DRD2 P14416 3/20 0.33
DRD3 P35462 3/20 0.33
CHRM1 P11229 2/20 0.33
DRD4 P21917 2/20 0.33
CYP2C9 P11712 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30507256 0.79 HSD11B1 (0.45) HSD11B1CA1CA2DRD2DRD3
SCHEMBL28905831 0.79 HSD11B1 (0.45) HSD11B1CA1CA2DRD2DRD3
SCHEMBL16811754 0.75 HSD11B1 (0.48) HSD11B1CA1CA2KMT2AMEN1
SCHEMBL31243801 0.75 HSD11B1 (0.48) HSD11B1CA1CA2KMT2AMEN1
SCHEMBL2750188 0.72 CA2 (0.57) HSD11B1CA1CA2DRD2DRD3
SCHEMBL13933197 0.72 HSD11B1 (0.46) HSD11B1CA1CA2KMT2AMEN1
SCHEMBL15370576 0.72 MEN1 (0.49) HSD11B1L3MBTL1CA1CA2KMT2A
Hydrogen Sulfide SCHEMBL6248782 0.71 CA2 (0.55) HSD11B1CA1CA2DRD2DRD3
SCHEMBL4056753 0.71 CA1 (0.51) HSD11B1L3MBTL1CA1CA2DRD2
SCHEMBL19212762 0.70 HSD11B1 (0.38) HSD11B1CA1CA2NPSR1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0937045-B1 N-ARYL SUBSTITUTED TETRAHYDROQUINOLINES LIGANDS FOR RETINOID RECEPTORS HAVING AGONIST, ANTAGONIST OR INVERSE AGONIST TYPE ACTIVITY ALLERGAN INC (US) 2004-04-28 EP disclosed